Ranbaxy Laboratories, India's largest drugmaker by sales, on Wednesday announced a four-fold surge in net profit for the quarter ended March 31 at Rs. 1246.8 crore.
The drugmaker, majority-owned by Japan's Daiichi Sankyo, had a net profit of Rs. 304.4 crore in the same period a year ago.
Consolidated net sales also shot up 55% to Rs. 3,700.2 crore from Rs. 2,145.3 crore last year.
"The focus on key products and markets ... has had a positive impact on performance during the quarter," said Arun Sawhney, MD, Ranbaxy.
Ranbaxy saw sales grow in most major markets, including north America, western Europe, Asia Pacific and active pharmaceutical ingredients business.